Zacks downgrades Vanda Pharmaceuticals stock to Strong Sell

Published on 10/08/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 50.53 million. Vanda Pharmaceuticals stock costs EUR 3.95 versus EUR 4.07, down 2.95 percent on October 8, 2026 in trading.

Key points in brief

Zacks Research downgraded Vanda Pharmaceuticals from Hold to Strong Sell in a report issued on Tuesday and reported by MarketBeat on October 8, 2026.
Vanda reported USD 50.53 million in second-quarter 2026 revenue and a USD 62.51 million net loss.
The Phase III HETLIOZ study shifted sleep onset 37.10 minutes earlier than placebo on September 29, 2026.
Lang & Schwarz quoted the stock at EUR 3.95 on October 8, 2026 at 5:14 p.m. CEST, down 2.95 percent from EUR 4.07.

VNDA, US9216591084, Illustration mit AI erstellt.

Vanda Pharmaceuticals stock (ISIN US9216591084) stood at EUR 3.95 at Lang & Schwarz on October 8, 2026 at 5:14 p.m. CEST, down 2.95 percent from the EUR 4.07 prior close. MarketBeat reported that Zacks Research had downgraded the company from Hold to Strong Sell in a research report issued on Tuesday.

Three milestones shape the story

On August 5, 2026, Vanda reported second-quarter revenue of USD 50.53 million and a net loss of USD 62.51 million, according to MarketBeat. On September 29, 2026, the company announced Phase III HETLIOZ results showing sleep onset 37.10 minutes earlier than placebo, as reported by FinanzNachrichten. On October 8, 2026, the Zacks rating change supplied the latest dated event in this sequence.

What does the trial result change?

The HETLIOZ result gives Vanda a potential expansion path for tasimelteon into delayed sleep-wake phase disorder. In the study, 60.00 percent of treated participants advanced sleep timing by at least 30 minutes, compared with 15.00 percent for placebo, according to FinanzNachrichten. The company said it plans to discuss the data with the FDA and submit a supplemental application, leaving regulatory execution as the next measurable step.

The second-quarter revenue result was 4.00 percent below the USD 52.60 million reported for the second quarter of 2025, while the net loss widened from USD 27.20 million to USD 62.51 million. The figures make the clinical result strategically important because commercial performance remains pressured while the pipeline seeks additional indications.

Next dates for VNDA

TradingView lists November 4, 2026 as the next reporting date for third-quarter 2026 results. The same calendar lists February 10, 2027 as the subsequent earnings date, giving investors two dated checkpoints after the September clinical announcement.

Stock remains below its yearly high

VNDA had a market capitalization of USD 266.10 million on October 8, 2026, while its Nasdaq 52-week range was USD 4.27 to USD 9.94. The Lang & Schwarz euro quote was therefore the immediate German-market reference, with the intraday price at EUR 3.95 and the prior close at EUR 4.07.

The further course of trading is shown by the continuously updated real-time quote of Vanda Pharmaceuticals stock.